Acromegaly is a hormonal disorder in which the body produces too much growth hormone, leading to the gradual, excessive growth of bones, soft tissue, and organs. In almost all cases, the source of that excess is a benign tumor on the pituitary gland, a pea-sized structure at the base of the brain that acts as the body’s hormonal command center.1PubMed. Growth Hormone Excess: Implications and Management The condition develops slowly over years, and many people live with it for a decade or more before anyone recognizes it. That delay matters, because the longer acromegaly goes untreated, the more damage it does to the heart, joints, metabolism, and skeleton.
What Actually Happens Inside the Body
The pituitary gland normally releases growth hormone in small pulses, mostly during sleep. Growth hormone travels to the liver, where it triggers the production of another hormone called insulin-like growth factor 1 (IGF-1). IGF-1 is the molecule that actually stimulates cell growth and reproduction throughout the body. In acromegaly, a pituitary tumor (called a somatotropinoma) pumps out growth hormone around the clock, which in turn keeps IGF-1 levels persistently high.2PubMed. Growth Hormone Excess: Implications and Management The result is relentless tissue growth in virtually every organ system. These tumors are overwhelmingly benign, meaning they don’t spread to other parts of the body, but they can grow large enough to press on nearby structures like the optic nerves.
In rare cases, acromegaly is caused not by a pituitary tumor but by a tumor elsewhere in the body that secretes either growth hormone or a signaling molecule that tells the pituitary to overproduce it. These ectopic cases are uncommon enough that the standard workup focuses squarely on the pituitary.
Acromegaly Versus Gigantism
Whether excess growth hormone causes acromegaly or gigantism depends entirely on timing. In children and adolescents whose growth plates have not yet fused, the surplus hormone drives dramatic increases in height, a condition called gigantism.3PubMed Central. Genetics of gigantism and acromegaly Once the growth plates close at the end of puberty, the long bones can no longer lengthen. Excess growth hormone after that point enlarges the hands, feet, jaw, and soft tissues instead, which is acromegaly.4The Journal of Clinical Endocrinology & Metabolism. Gigantism The underlying hormonal problem is the same in both conditions; only the skeleton’s ability to grow in length differs.
Recognizing the Physical Signs
The changes caused by acromegaly are slow enough that friends and family often don’t notice until they compare old photographs to a person’s current appearance. The face coarsens: the brow ridge becomes more prominent, the nose and ears widen, the lips thicken, and the jawbone juts forward, sometimes causing the teeth to spread apart.5PubMed. Acromegaly: clinical features at diagnosis Skin wrinkles and nasolabial folds deepen. The hands and feet broaden, mostly from soft-tissue swelling rather than bone growth, and people frequently report that their rings no longer fit or that they have gone up several shoe sizes over the years.6PubMed Central. Acromegaly
Enlargement of the hands and feet combined with the characteristic facial changes is so central to the clinical picture that textbooks traditionally describe it as the hallmark of acromegaly.7PubMed Central. Acromegaly without acral changes: A rare presentation Beyond appearance, patients often deal with excessive sweating, deepening of the voice, chronic fatigue, headaches, and joint pain. Internal organs can enlarge as well: the heart, liver, and kidneys may all grow beyond normal size.
Why the Heart Takes a Hit
Cardiovascular disease is the leading cause of death in untreated acromegaly. Chronically elevated growth hormone and IGF-1 directly stimulate heart muscle cells to grow, eventually producing a specific form of heart disease called acromegalic cardiomyopathy. The hallmarks are thickening of both ventricles, trouble relaxing between beats (diastolic dysfunction), and, in advanced cases, weakened pumping ability and heart failure.8PubMed Central. Cardiovascular Disease in Acromegaly Valve problems and abnormal heart rhythms also become more common.9PubMed Central. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management
High blood pressure is reported in roughly a third of acromegaly patients and is among the strongest predictors of cardiac complications and early death.10PubMed Central. CARDIOVASCULAR COMPLICATIONS OF ACROMEGALY The encouraging news is that controlling the hormone excess, whether through surgery or medication, can partially reverse these cardiac changes, particularly when the disease is caught before the heart has been remodeled beyond a point of recovery.11PubMed Central. Cardiovascular Disease in Acromegaly
Metabolic Fallout and Joint Disease
Growth hormone and insulin work against each other in important ways. Excess growth hormone makes the body’s cells resistant to insulin, which pushes blood sugar levels up. This cascade from insulin resistance to glucose intolerance to outright diabetes is a central metabolic feature of acromegaly and is tightly linked to disease activity.12PubMed Central. Insulin Resistance in Patients With Acromegaly Insulin resistance also feeds into hypertension, sleep apnea, and polycystic ovary problems, making it a kind of metabolic hub for many of acromegaly’s complications.
Joint disease is perhaps the most stubborn consequence. Up to about 70% of patients already show signs of osteoarthritis at the time of diagnosis.13Reumatologia. Skeletal complications in acromegaly This is not ordinary wear-and-tear arthritis. Excess growth hormone drives abnormal thickening of cartilage and new cartilage growth in places it shouldn’t be (ectopic chondrogenesis), along with inflammation that affects all the tissues in and around the joint.14PubMed Central. Excess Growth Hormone Triggers Inflammation-Associated Arthropathy, Subchondral Bone Loss, and Arthralgia Even after acromegaly is successfully treated and hormone levels return to normal, arthropathy prevalence remains many times higher than in the general population, making it a lasting source of disability.15Reumatologia. Skeletal complications in acromegaly Arthritis can also be among the earliest symptoms, showing up before anyone suspects a hormonal disorder.16PubMed Central. Osteoarticular changes in acromegaly
Cancer Risk
Because IGF-1 promotes cell growth and inhibits cell death, there has long been concern that acromegaly raises the risk of cancer. The data are strongest for colorectal cancer. A meta-analysis found that people with acromegaly have roughly four times the odds of developing colon cancer and about two-and-a-half times the odds of developing colon adenomas (precancerous polyps) compared with the general population.17PubMed Central. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis There is also an increased risk that precancerous lesions will transform into full-blown cancer over a patient’s lifetime, making colorectal malignancy a major disease-related complication.18PubMed Central. Colonic Cancer and Acromegaly For this reason, regular colonoscopies are standard practice once acromegaly is diagnosed.
How Acromegaly Is Diagnosed
Diagnosis starts with blood tests. An elevated IGF-1 level for the patient’s age and sex is the first red flag. To confirm, doctors administer an oral glucose tolerance test: drinking a sugary solution normally suppresses growth hormone release, but in acromegaly, growth hormone levels stay stubbornly high. Even in patients with an elevated IGF-1 and suspicious symptoms, if growth hormone suppresses normally during this test, acromegaly is very unlikely.19PubMed Central. Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1?
Once the hormonal diagnosis is confirmed, an MRI of the pituitary is performed to find the tumor. These tumors come in different sizes and MRI characteristics. The signal intensity on certain MRI sequences (T2-weighted images) turns out to carry practical information: tumors that appear dark on T2 imaging tend to be smaller and produce higher IGF-1 levels, while those that appear bright tend to be larger and more likely to invade surrounding structures like the cavernous sinus.20Endocrine-Related Cancer. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences This MRI signal also predicts how well the tumor responds to certain medications, which helps guide treatment choices.21PubMed Central. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas
The Problem of Delayed Diagnosis
Because the changes happen so gradually, acromegaly is frequently diagnosed years or even decades after it begins. That delay is not just an inconvenience. A large study found that the average number of coexisting health problems rose significantly with longer diagnostic delay, and patients whose diagnosis took the longest had a meaningfully higher death rate, with standardized mortality nearly twice that of the general population.22PubMed. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality Bone health suffers especially: among patients whose diagnosis was delayed more than ten years, roughly three-quarters developed new vertebral fractures, compared with just 5% of those caught within five years.23PubMed Central. Impact of the diagnostic delay of acromegaly on bone health
A large Chinese cohort showed a similar pattern: patients who waited four or more years from symptom onset to diagnosis had a higher proportion of comorbidities than those diagnosed sooner.24PubMed Central. Biochemical remission, diagnostic delays, and comorbidities of acromegaly in China: a large single-centre retrospective study These findings have pushed some endocrinologists to advocate for broader awareness among primary care physicians, dentists (who may notice jaw and tooth changes), and even optometrists (who may detect visual field loss from a tumor pressing on the optic chiasm).
Treatment Options
Surgery is the first-line treatment for most patients. The operation is performed through the nose and sinuses (transsphenoidal approach), and the goal is complete removal of the tumor. For smaller tumors (microadenomas), surgical cure rates are excellent. For larger tumors that have extended beyond the pituitary fossa, remission rates drop. One series of purely endoscopic surgeries reported overall remission in about 61% of patients, with the main factors predicting persistent disease being larger tumor size and invasion into the cavernous sinus.25PubMed Central. Early Predictors of Remission in Acromegaly Patients after Pure Endoscopic Endonasal Transsphenoidal Surgery A similar study found that all microadenomas were cured surgically, while about 61% of macroadenomas achieved remission.26The Journal of Clinical Endocrinology & Metabolism. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome
When surgery alone doesn’t normalize hormone levels, medications step in. The first-line drugs are somatostatin analogs, synthetic versions of a natural hormone that tells the pituitary to stop releasing growth hormone. Octreotide LAR and lanreotide are the two most widely used. Lanreotide normalizes IGF-1 in roughly 35% to 70% of patients, depending on whether it is being used as the first treatment or as a backup after surgery.27PubMed. Lanreotide for the treatment of acromegaly In a head-to-head comparison, octreotide LAR achieved somewhat greater growth hormone suppression than lanreotide at standard doses.28PubMed. A comparison of lanreotide and octreotide LAR for treatment of acromegaly A newer somatostatin analog called pasireotide, which binds to a broader range of somatostatin receptors, is reserved for patients who don’t respond to the older drugs. In one study of patients who had failed first-generation somatostatin analogs, only about 15% achieved full biochemical control on pasireotide.29PubMed Central. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
For patients who remain resistant to somatostatin analogs, pegvisomant offers a different approach. Rather than reducing growth hormone production, pegvisomant blocks the growth hormone receptor in the liver, preventing the signal from reaching the cells that produce IGF-1. In a randomized trial, the highest dose normalized IGF-1 levels in 89% of patients, along with measurable decreases in ring size, soft-tissue swelling, sweating, and fatigue.30PubMed. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant In a small group of patients who had proven completely resistant to somatostatin analogs, pegvisomant normalized IGF-1 in every one of them.31PubMed. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs Over two decades of use, it has proven safe; early fears that blocking the receptor might cause the pituitary tumor to grow have not materialized, though a small number of patients develop liver enzyme abnormalities or injection-site reactions.32PubMed. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess
Radiation therapy, particularly stereotactic radiosurgery (Gamma Knife), serves as a third-line option when surgery and medications together cannot achieve control. It can bring a substantial proportion of patients into remission, but the effect unfolds over years, and the main long-term risk is damage to the normal pituitary tissue, leading to deficiencies in other hormones.33PubMed Central. Gamma knife radiosurgery for acromegaly Reassuringly, a study designed to look for delayed brain effects found no significant cognitive decline after Gamma Knife treatment, though new hormonal deficiencies did develop in some patients during follow-up.34PubMed. Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study
The Genetic Side
Most pituitary tumors that cause acromegaly arise spontaneously, with no inherited predisposition. However, a small fraction occur in a familial context. Several hereditary syndromes have been linked to growth-hormone-secreting tumors, and researchers have identified specific genes whose mutations can predispose a person to developing a somatotropinoma.35PubMed Central. The genetic background of acromegaly Mutations in a gene called AIP, for instance, are disproportionately common in young patients with large tumors, and testing for AIP and other gene mutations has become part of the evaluation when a pituitary adenoma appears in a child or teenager.36PubMed Central. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in a large cohort of children and adolescents with pituitary adenomas If a genetic cause is found, screening of family members can sometimes catch tumors before they cause symptoms.
Cognitive and Emotional Effects
Acromegaly’s impact is not limited to the body. Over the past several decades, a growing number of studies have found that patients often experience personality changes, difficulty with memory and attention, and reduced cognitive flexibility.37PubMed Central. Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly A prospective study that tracked patients from active disease into remission found that cognitive functions, memory, and selective attention all improved once hormone levels were brought under control. Depression scores also dropped, and quality-of-life ratings rose substantially.38PubMed. Impact of disease activity on cognitive and psychological outcomes in acromegaly: A prospective study
Quality of life more broadly takes a real hit. Research using a disease-specific questionnaire (AcroQoL) consistently shows that patients with biochemically uncontrolled acromegaly score significantly worse than those in remission, particularly in domains related to physical appearance and psychological well-being.39PubMed. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL) Achieving remission improves appearance-related quality scores, though some patients continue to struggle with body image even after their hormone levels normalize, because many of the bony and soft-tissue changes are irreversible.40PubMed. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire
How the Condition Got Its Name
The word acromegaly comes from the Greek roots for “extremity” (akron) and “enlargement” (megas). The French neurologist Pierre Marie coined the term in 1886 after describing two patients with the characteristic hand, foot, and facial enlargement.41PubMed. The History of Acromegaly Autopsies after Marie’s initial reports found an enlarged pituitary in nearly every patient, and the connection between the gland and the disease was soon established.42Journal of Neurosurgery. Early descriptions of acromegaly and gigantism and their historical evolution as clinical entities It was Harvey Cushing who, in 1909, proposed that a “hormone of growth” from the pituitary was the underlying driver and demonstrated that removing the enlarged gland could reverse symptoms.43PubMed Central. GIGANTISM AND ACROMEGALY THROUGH HISTORY Growth hormone itself wasn’t isolated until decades later, but Cushing’s insight laid the foundation for the surgical approach that remains the first-line treatment today.
Acromegaly in Cats
Humans are not the only species affected by growth hormone excess. Feline acromegaly, sometimes called hypersomatotropism, is an increasingly recognized condition in cats, particularly older males. It typically presents as diabetes that is unusually difficult to control with insulin, because the excess growth hormone creates severe insulin resistance.44PubMed Central. Feline acromegaly: an essential differential diagnosis for the difficult diabetic Veterinary researchers have found that a significant proportion of cats with hard-to-manage diabetes actually have underlying acromegaly, making it an important diagnosis to consider in any diabetic cat that doesn’t respond to standard therapy. The disease in cats shares a remarkable overlap with the human version: pituitary tumors are the usual cause, and the physical signs include weight gain, broadening of the facial features, and organ enlargement. Treatment options in cats are more limited, but radiation therapy and newer medical approaches are gradually becoming available at specialty veterinary centers.